Skip to main content

Featured

20 Turkish Soldiers Killed in Georgia Military Plane Crash

Members of emergency services work at the site of the Turkish C-130 military cargo plane crash near the Azerbaijani border, in Sighnaghi municipality, Georgia. Turkey’s Ministry of Defense announced that 20 soldiers were killed when a military transport plane crashed in Georgia . The aircraft, a C-130 cargo plane, had departed from Azerbaijan and was en route to Turkey when communication was lost shortly after takeoff. Georgian emergency teams reported that 18 bodies were recovered at the crash site , with search operations continuing to locate the remaining victims. Witnesses shared footage showing the plane breaking apart mid-air before spiraling down into farmland near the Azerbaijani border. This tragedy is Turkey’s deadliest military aviation accident in recent years . Both Turkish and Georgian authorities have launched investigations, and officials confirmed that the aircraft’s black box has been recovered . President Recep Tayyip Erdoğan expressed condolences to the families...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment